Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

OpenAI said Wednesday it is pushing for mandatory national AI safety requirements, adding that until the U.S. Congress acts, the ChatGPT maker will continue supporting state AI legislation.

Anthropic CEO Dario Amodei called for a slowdown in frontier AI capability development in a September essay, warning that ...

On2, Anthropic CEO Dario Amodei published an essay urging AI companies to slow improvements in frontier-model capabilities ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Get the latest news on Recursion Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Recursion Pharmaceuticals performance ...